MediWound Ltd. is classed by the SEC under Medicinal Chemicals & Botanical Products (industry code 2833), based in Yavne, IL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $6 million and a loss of $24 million (its filed statements).
Product businessMedicinal Chemicals & Botanical ProductsYavne, ILfilings since 20137 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2833, Medicinal Chemicals & Botanical Products); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.7 out of ten, 7 of 9 metrics filed and 2 estimated: past 4.9 out of ten, present 2.7 out of ten, future 3.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.3 out of ten. No warning events in its filings since 2017. 83rd percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.7 out of ten. +30.4% a year over 10 filed years; profitable in 1 of 10. 37th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 2.5 out of ten. CrossAssetData estimate 2.5/10, confidence 35 of 100 (one part). 25th percentile among 18 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.9 out of ten. ROE -55%: lost 55¢ per shareholder dollar. Leverage 49%: owes 49¢ per asset dollar. 29th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 0.9 out of ten. bottom 9% of 18 in its family; net margin -140.8%. 9th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 3.8 out of ten. bottom 38% of 18 in its family for room to expand. 38th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.0 out of ten. top 50% of 18 in its family for growth drivers. 50th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 2.5 out of ten. bottom 25% of 18 in its family for expectations against reality. 25th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 4, 2026-09-02. Filings on record since 2013. Read from EDGAR 2026-10-12.
Who runs it
Gonen, Ofer (Chief Executive Officer); Luxenburg, Kalfon Hana (Chief Financial Officer); Hess, Shmuel (COO & Chief Commercial Officer); Klinger, Ety (Chief Medical Officer); Ben, Yaakov Aya (VP Clinical & Reg. Affairs); Meyer, Yaron (EVP, GC & Corp. Secretary); Rubinstein, Samuel (director); Shamir, Nachum (director); Fox, David Morton (director); Driver, Vickie Rae (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.